European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 
03 Sep 2006

Evaluation of multivessel disease Symposium 

Prof. Franz Weidinger 

Prof. Franz Weidinger
Topics: Invasive Imaging: Cardiac Catheterisation and Angiography
Session number: 151000
Session title: Evaluation of multivessel disease
Authors: Weidinger, F. Innsbruck, Austria
Evaluation of coronary lesions has for many years relied on the assessment of the “lumenogram” but it has changed nowadays to more physiologic measurements of haemodynamic significance, Professor E Eeckhout from Lausanne pointed out.

Modern tools for such comprehensive assessment of stenosis severity include non-invasive methods, such as scintigraphiy, multi-slice computed tomography (MSCT), magnetic resonance imaging (MRI) and positron emission tomography (PET), as well as invasive methods. In multivessel CAD (MVD) the appropriate choice of treatment is particularly important and, thus, the adequate use of available diagnostic tools should be decided carefully.

Dr J M Knuuti from Turku, Finland summarised the data from scintigraphic evaluation, which showed good correlation between size and number of perfusion defects and clinical end points. The inclusion of information about left ventricular size and function by gated SPECT analysis further enhances the prognostic impact of myocardial scintigraphy.

MRI perfusion studies are promising for improved evaluation of functional consequences of coronary stenoses, and studies are ongoing to establish the accuracy of stress perfusion and delayed enhancement with this imaging modality. PET provides quantitative, functional information on perfusion, function and viability of the myocardium, but has the limitation of low availability, high cost and limited prognostic data for multivessel disease.

Dr. P Vanhoenacker from Aalst, Belgium, then discussed the current value of MSCT in evaluating CAD, where it is recommended only for patients with the intermediate pre-test likelihood of CAD in current guidelines. More recent fields of research include the assessment of “soft”, potentially vulnerable plaque, exclusion of significant CAD in enzyme-negative acute chest pain and the post CABG patient with atypical symptoms or before planned bypass graft PCI. To date, however, many obstacles have to be overcome before MSCT can become a reliable tool for assessing stenosis severity and plaque morphology.

Fractional flow reserve is the invasive method to assess stenosis severity and is now the only well established technique for this purpose in the cath lab. Prospective studies have proven the safety of deferring patients with intermediate lesions for PCI at a latter time period, Dr W F Fearon from Stanford University in the USA reported.

Conclusion The correct choice of treatment in patients with multivessel disease remains a challenge and should involve the best diagnostic methods available.

Whether decision-making is based on non-invasive imaging or in-cath lab assessment of lesion severity depends largely on the expertise available, on the pending results of ongoing studies and, last but not least, on the preference and clinical judgement of the treating physician.


The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.